Pappas Capital portfolio company Minoryx Therapeutics has met the primary endpoint in its pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy. https://lnkd.in/eBd-8r76
Pappas Capital
Venture Capital and Private Equity Principals
Durham, North Carolina 2,439 followers
About us
Founded in 1994, Pappas Capital is a global venture capital and commercial development firm that specializes in investments in next-generation life science, agriculture, and technology companies across the United States and Canada, with select investments in Asia and Europe. Whether you’re looking for capital or have capital to invest, contact us and learn how we can put our expertise to work for you.
- Website
-
http://pappas-capital.com
External link for Pappas Capital
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- Durham, North Carolina
- Type
- Privately Held
- Founded
- 1994
- Specialties
- Biotechnology, Biopharmaceuticals, and Medical Devices
Locations
-
Primary
Get directions
2520 Meridian Pkwy
Suite 400
Durham, North Carolina 27713, US
Employees at Pappas Capital
-
Barry Myers
Professor and Director, Life Sciences Venture Capital
-
Patrick Daly
Global VP & GM @ IQVIA | Executive Advisor, MedTech Pappas Capital
-
Thomas Mathers
Founder, President and CEO at Allievex Corporation
-
Mike Grey
Chair or Executive Chair Mirum Pharmaceuticals, Reneo Pharmaceuticals, Spruce Biosciences, Plexium and Sorriso Pharmaceuticals
Updates
-
Pappas Capital reposted this
We are excited to share that an article discussing the treatment of conjunctival melanoma cell lines with bel-sar was recently published in IOVS, an Association for Research in Vision and Ophthalmology (ARVO) Journal. A special thanks to Dr. Martine Jager for her partnership on the article. A link to the full article can be found here: bit.ly/3YJVyJk
-
-
Congratulations to Pappas Capital portfolio company EarthOptics on the successful completion of its $24 million financing. https://lnkd.in/gmz5RCta
EarthOptics Secures $24 Million in Financing to Drive Expansion and Revolutionize Soil Digitization
globenewswire.com
-
Pappas Capital reposted this
Yesterday at #AASLD2024, we showcased exciting new data supporting our mission to develop a functional cure for chronic Hepatitis B Virus infection (#HBV), using Tune-401 – an epi-silencing drug now approved for clinical trial in New Zealand. This progress is a testament to the potential of epi-editing to deliver lasting impacts in common and chronic diseases. #LiverDisease #HepatitisBCure #EpigenomeEditing LEARN MORE: https://lnkd.in/erT36fgm
AASLD 2024: Tune Therapeutics Shows Near-Complete HepB Virus Repression with Tune-401 Epigenetic Silencer
businesswire.com
-
Congratulations to Pappas portfolio company Tune Therapeutics on their approval to initiate their Phase 1b trial!
Breaking news from Tune Therapeutics: we have just received approval from New Zealand's Medsafe to initiate a Phase 1b clinical trial for Tune-401 – our first-in-class epigenetic silencing therapy aimed at treating chronic Hepatitis B. This innovative approach targets the virus at the DNA level, offering new hope to millions of people facing long-term HBV infection. Tune-401 will be the first epigenetic therapy to enter clinical trials for an infectious disease. #Epigenetics #HepatitisB #HBV #GeneTherapy #HealthcareInnovation #Epigenetics #HepatitisB https://lnkd.in/eEvnSYS9
Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B
businesswire.com
-
Congratulations to Pappas Capital portfolio company Enlaza Therapeutics on being named to C&EN's prestigious list of Top 10 Startups to Watch!
We're thrilled to share that Enlaza Therapeutics has been named to C&EN's prestigious list of Top 10 Startups to Watch! This recognition highlights our work in pioneering a groundbreaking therapeutic class—covalent biologics—that holds the potential for enhanced efficacy and safety. Our platform offers vast possibilities across all therapeutic areas. Huge thanks to our team for their dedication in driving this vision forward! See the list here: https://lnkd.in/gunzUhhJ #10StartUpsToWatch #covalentbiologics #WarLock #financing #biotech #SanDiego #oncology #cancer #cancers #antibodydrugconjugates #ADC
-
-
Dr. Ernest Mario June 12, 1938 – October 20, 2024 Pappas Capital is deeply saddened to announce the passing of Dr. Ernest “Ernie” Mario, Senior Venture Partner and one of the founders of Pappas’ venture capital business. Ernie joined Pappas Capital’s Scientific Advisory Board in 2002 and became a Senior Venture Partner in 2011. He helped to build Pappas Capital into a leading life science venture capital firm and was a friend and mentor to the entire Pappas team. His work at Glaxo and Duke University, as well as his leadership roles with numerous North Carolina-based life science companies had a significant impact on the growth and development of the state’s life science ecosystem. Ernie was a leader of leaders. He mentored research, development and commercial executives around the world. His impact on patients was profound, bringing forward numerous first and best in class medicines and building organizations to support their growth and development. His focus on academic science at Duke University and Rutgers University is notable and helped ensure their leadership as research intensive organizations. Ernie built his life around helping people and his legacy will be the mentoring that he provided to family, friends, and colleagues. He had a unique way of inspiring one to feel great and be eager to do more. His leadership and counsel will be greatly missed. https://lnkd.in/e44MZ7QG
-
-
Congratulations to Pappas portfolio company Aura Biosciences on their positive Phase 1 data!
This afternoon, Aura announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer. Read the full release here: bit.ly/4dZ9Efu
-
-
Art Pappas will be speaking on a panel at #BioFuture2024! Join the discussion on the latest topics shaping the future of #healthcare alongside industry leaders and trailblazing companies. Register at www.BioFuture.com!
-
-
Congratulations to Kathleen Sereda Glaub on her appointment to CEO of Pappas portfolio company CuraSen Therapeutics, Inc.! https://lnkd.in/e-33pPna
CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer
businesswire.com